Enantiopure β3-neopentylglycine: synthesis and resolution
摘要:
A procedure has been developed for the large scale synthesis of enantiopure beta(3)-neopentylglycine and its Cbz-protected derivative. The synthetic route developed in Out laboratory features Cbz-protection of the racemic beta-amino acid followed by resolution with L-norephedrine and provides the enantiomerically Pure Cbz-beta-neopentylglycine in good yield and excellent enantiopurity. No toxic or dangerous chemicals are used, allowing the scale-up of this procedure without major safety concerns. (c) 2009 Elsevier Ltd. All rights reserved.
Enantiopure β3-neopentylglycine: synthesis and resolution
摘要:
A procedure has been developed for the large scale synthesis of enantiopure beta(3)-neopentylglycine and its Cbz-protected derivative. The synthetic route developed in Out laboratory features Cbz-protection of the racemic beta-amino acid followed by resolution with L-norephedrine and provides the enantiomerically Pure Cbz-beta-neopentylglycine in good yield and excellent enantiopurity. No toxic or dangerous chemicals are used, allowing the scale-up of this procedure without major safety concerns. (c) 2009 Elsevier Ltd. All rights reserved.
Enantiopure β3-neopentylglycine: synthesis and resolution
作者:Matthijs K.J. ter Wiel、Mirjam Arnold、Sandra Peter、Ingo Troltsch、Stefan Merget、Florian Glaser、Michael Schwarm、Harjinder S. Bhatti、Biju Kuriakose、Suryakant S. Pol、Mohanasundaram Balamurugan、Viral V. Joshi
DOI:10.1016/j.tetasy.2009.01.018
日期:2009.3
A procedure has been developed for the large scale synthesis of enantiopure beta(3)-neopentylglycine and its Cbz-protected derivative. The synthetic route developed in Out laboratory features Cbz-protection of the racemic beta-amino acid followed by resolution with L-norephedrine and provides the enantiomerically Pure Cbz-beta-neopentylglycine in good yield and excellent enantiopurity. No toxic or dangerous chemicals are used, allowing the scale-up of this procedure without major safety concerns. (c) 2009 Elsevier Ltd. All rights reserved.